ArticleBiomarker research2020
Clinical characteristics and prognostic value of the
Article in Biomarker research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- Pooled it
- Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.Cancer communications (London, England) · 2025Trial
- Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.Journal of cancer research and clinical oncology · 2023Trial
- Targeting TROP-2 in treatment-resistant non-small cell lung cancer harboring theOncology letters · 2026Article
- A Lactylation-based Gene Signature in Lung Adenocarcinoma Provides a Novel Perspective to Predict the Prognosis and Therapeutic Response.Current medicinal chemistry · 2026Article
- Synergistic effects of oxymatrine and GIMAP8 in inhibiting lung adenocarcinoma progression via regulating Wnt/β-catenin pathway.Cytotechnology · 2025Article
- Mechanisms and current advances in treatingChinese medical journal pulmonary and critical care medicine · 2025Review
- ATR expression as a prognostic biomarker inJournal of thoracic disease · 2025Article
- Next-generation sequencing in early-stage multiple primary lung cancer: The prognostic significance of genomic accumulation status and BCL2L11Translational oncology · 2025Article
- Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials.Cancers · 2024Article
- Study of the mass balance, biotransformation, and safety of [Journal of biomedical research · 2024Article
- Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.Journal of cancer research and clinical oncology · 2024Article
- Drug development and evidence for lung cancer targeted therapy in Eastern Asia.The Lancet regional health. Western Pacific · 2024Review
- Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report.Clinical case reports · 2024Article
- Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene-A Literature Review and Single-Center Experience.Biomedicines · 2024Review
- Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASGFrontiers in pharmacology · 2024Article
- The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2023Article
- Characteristics and prognostic analysis of patients with detectedTranslational lung cancer research · 2023Article
- Regulation of Ferroptosis in Lung Adenocarcinoma.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe
methodsNext-generation sequencing was used to confirm the
resultsIn the mCohort, 3998 patients (9.8%) were confirmed to harbor a
conclusionsIn the largest sample used thus for, our study found that approximately 10% of Chinese NSCLC patients had
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.